SHANGHAI RIGHTONGENE BIOTECHNOLOGY CO., LTD. Shanghai Rightongene Biotechnology Co., Ltd. Share Price
Equities
688217
CNE100005212
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.95 CNY | +0.34% |
|
+6.40% | -33.06% |
| Sales 2024 * | 311M 42.93M 3.58B | Sales 2025 * | 375M 51.76M 4.32B | Capitalization | 1.34B 185M 15.4B |
|---|---|---|---|---|---|
| Net income 2024 * | 12M 1.66M 138M | Net income 2025 * | 14M 1.93M 161M | EV / Sales 2024 * | 4.3 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 3.57 x |
| P/E ratio 2024 * |
114
x | P/E ratio 2025 * |
95.8
x | Employees | 501 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 54.68% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.34% | ||
| 1 week | +6.40% | ||
| Current month | -13.04% | ||
| 1 month | -10.80% | ||
| 3 months | -21.24% | ||
| 6 months | -36.03% | ||
| Current year | -33.06% |
1 week
22.51
24.22
1 month
21.8027.98
Current year
19.3436.35
1 year
19.3443.79
3 years
19.34133.67
5 years
19.34133.67
10 years
19.34133.67
| Managers | Title | Age | Since |
|---|---|---|---|
Hui Xiong
CEO | Chief Executive Officer | 52 | 17/12/17 |
Yan Li
DFI | Director of Finance/CFO | 42 | 27/20/27 |
Jun Xiong
BRD | Director/Board Member | 48 | 01/15/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Xue Wei Yuan
BRD | Director/Board Member | 52 | 13/18/13 |
Gui Ying Zhao
BRD | Director/Board Member | 70 | 13/18/13 |
Hui Xiong
CEO | Chief Executive Officer | 52 | 17/12/17 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 23.95 | +0.34% | 152,256 |
| 25/24/25 | 23.87 | +1.23% | 203,996 |
| 24/24/24 | 23.58 | +2.34% | 241,130 |
| 23/24/23 | 23.04 | +0.83% | 178,168 |
| 22/24/22 | 22.85 | +1.51% | 201,333 |
End-of-day quote Shanghai S.E., April 26, 2024
More quotes
Shanghai Rightongene Biotechnology Co Ltd is a China-based company principally engaged in the research and development, production and sales of in-vitro diagnostic products, as well as the provision of scientific research and testing services. The Company's main products include leukemia molecular diagnostic kits and lymphoma molecular diagnostic kits. The Company mainly provides precise gene and antigen testing services for patients with blood diseases, solid tumors and infectious diseases. The Company also provides scientific research services applied in basic research, disease typing, drug adaptability and target genetic testing. The Company mainly conducts its businesses within domestic market.
Calendar
23/08/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
23.95
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -33.06% | 185M | |
| +0.89% | 12.8B | |
| -10.29% | 7.61B | |
| -1.16% | 4.51B | |
| +5.74% | 4.49B | |
| -50.70% | 3.3B | |
| +12.21% | 2.73B | |
| -16.13% | 2.02B | |
| -11.50% | 1.73B | |
| -5.02% | 1.64B |
- Stock Market
- Equities
- 688217 Stock
